Correspondence 0001104659-24-121087 from Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443) (MIST)
Milestone Pharmaceuticals Inc. (MIST) (CIK 0001408443)
Date: Nov. 20, 2024 · CIK: 0001408443 · Accession: 0001104659-24-121087
AI Filing Summary & Sentiment
File numbers found in text: 333-283162
Letter
Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montréal, Québec CA H4M 2X6
VIA EDGAR
November 20, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
Re: Milestone Pharmaceuticals Inc.
Registration Statement on Form S-3
File No. 333-283162
Acceleration Request
Requested Date: Friday, November 22, 2024
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-283162) (the “Registration Statement”) to become effective on Friday, November 22, 2024, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.
The Registrant hereby authorizes each of Ryan S. Sansom and Sarah E. Curry of Cooley LLP to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Sarah E. Curry of Cooley LLP, counsel to the undersigned registrant, at (212) 479-6652.
[Signature Page Follows]
Sincerely,
Milestone Pharmaceuticals Inc.
Show Raw Text
CORRESP
1
filename1.htm
Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montréal, Québec CA H4M 2X6
VIA EDGAR
November 20, 2024
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Chris Edwards
Re:
Milestone Pharmaceuticals Inc.
Registration Statement on Form S-3
File No. 333-283162
Acceleration Request
Requested Date:
Friday, November 22, 2024
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and
Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-283162)
(the “Registration Statement”) to become effective on Friday, November 22, 2024, at 4:00 p.m. Eastern
Time, or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the
Staff.
The Registrant hereby authorizes each of Ryan S. Sansom and Sarah E.
Curry of Cooley LLP to make such request on its behalf.
Once the Registration Statement has been declared
effective, please orally confirm that event with Sarah E. Curry of Cooley LLP, counsel to the undersigned registrant, at (212) 479-6652.
[Signature
Page Follows]
Sincerely,
Milestone Pharmaceuticals Inc.
By:
/s/ Joseph Oliveto
Joseph Oliveto
Chief Executive Officer
cc:
Amit Hasija, Milestone Pharmaceuticals Inc.
Ryan S. Sansom, Cooley LLP
Sarah E. Curry, Cooley LLP